Similarly, for the anti-PD1/PDL1-treated renal cell cancer patients [25,26], the immune score specific to KIRC was calculated; for the anti-PDL1-treated bladder urothelial tumor (bladder or ureter as tissue of origin) patients [25], the immune score specific to BLCA was calculated; for anti-PD1 treated non-small cell lung cancer patients, the immune score specific to LUAD was calculated; and for anti-PD1 treated gastric cancer patients, the immune score specific to STAD was calculated. This evidence concerns the gene PDCD1 and renal cell adenocarcinoma.